ATE427106T1 - Die verwendung von sphingolipiden zur senkung der cholesterin- und triglyzeridspiegel im plasma. - Google Patents

Die verwendung von sphingolipiden zur senkung der cholesterin- und triglyzeridspiegel im plasma.

Info

Publication number
ATE427106T1
ATE427106T1 AT04703544T AT04703544T ATE427106T1 AT E427106 T1 ATE427106 T1 AT E427106T1 AT 04703544 T AT04703544 T AT 04703544T AT 04703544 T AT04703544 T AT 04703544T AT E427106 T1 ATE427106 T1 AT E427106T1
Authority
AT
Austria
Prior art keywords
sphingolipids
cholesterol
triglyceride
triglyceride levels
plasma cholesterol
Prior art date
Application number
AT04703544T
Other languages
German (de)
English (en)
Inventor
Willem Nieuwenhuizen
Original Assignee
Tno
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32773655&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE427106(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from NL1022442A external-priority patent/NL1022442C2/nl
Application filed by Tno filed Critical Tno
Application granted granted Critical
Publication of ATE427106T1 publication Critical patent/ATE427106T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/40—Effervescence-generating compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT04703544T 2003-01-20 2004-01-20 Die verwendung von sphingolipiden zur senkung der cholesterin- und triglyzeridspiegel im plasma. ATE427106T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL1022442A NL1022442C2 (nl) 2003-01-20 2003-01-20 Toepassing van lipide ter verbetring van de opname van nutrienten en (farmaceutisch) actieve stoffen.
EP03078141 2003-10-06

Publications (1)

Publication Number Publication Date
ATE427106T1 true ATE427106T1 (de) 2009-04-15

Family

ID=32773655

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04703544T ATE427106T1 (de) 2003-01-20 2004-01-20 Die verwendung von sphingolipiden zur senkung der cholesterin- und triglyzeridspiegel im plasma.

Country Status (7)

Country Link
US (1) US7968529B2 (enExample)
EP (1) EP1585508B1 (enExample)
JP (1) JP2006516280A (enExample)
AT (1) ATE427106T1 (enExample)
DE (1) DE602004020316D1 (enExample)
ES (1) ES2325260T3 (enExample)
WO (1) WO2004064820A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006516280A (ja) 2003-01-20 2006-06-29 ネーデルランドセ オルガニサティエ フォール トエゲパストナトールヴェテンシャッペリク オンデルゾエク ティエヌオー 血漿コレステロール及びトリアシルグリセロールレベルを減少するためにスフィンゴ脂質を使用する方法
NL1022443C2 (nl) 2003-01-20 2004-07-22 Tno Sphingolipiden voor verbetering van de samenstelling van de darmflora.
US20050196461A1 (en) * 2004-01-14 2005-09-08 Udell Ronald G. Ceramide formulations suitable for oral administration
JP5154218B2 (ja) * 2004-03-16 2013-02-27 ネーデルランドセ オルガニサティエ フォール トエゲパスト−ナトールヴェテンシャッペリク オンデルゾエク ティエヌオー ２型糖尿病、インスリン抵抗性及びメタボリック症候群の治療及び予防においてスフィンゴ脂質を使用する方法
JP4359204B2 (ja) * 2004-03-19 2009-11-04 花王株式会社 皮膚保湿用食品
EP1618876A1 (en) * 2004-07-19 2006-01-25 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Use of sphingolipids for prevention and treatment of atherosclerosis
US7648714B2 (en) 2004-08-05 2010-01-19 Kao Corporation Food for skin moisture retention
DE102004052697A1 (de) * 2004-10-29 2006-05-04 Haehner, Thomas, Dr. Pharmazeutische Zubereitungen zur Behandlung von Folgen des Alkoholmissbrauchs, Hepatitis, Pankreatitis, Alzheimererkrankung, Morbus Parkinson, Diabetes, toxischen Nierenerkrankungen, Reperfusionsschäden, der Arteriosklerose sowie als Antidote gegen Umweltgifte und Medikamentenintoxikation
AU2005310341A1 (en) 2004-11-30 2006-06-08 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Sphingolipids in treatment and prevention of steatosis and of steatosis or of hepatotoxicity and its sequelae
JP4040069B2 (ja) * 2005-08-09 2008-01-30 株式会社ミツカングループ本社 脳機能改善用組成物
JP2008013579A (ja) * 2005-08-22 2008-01-24 Mitsukan Group Honsha:Kk 筋肉損傷抑制組成物
JP4040070B2 (ja) * 2005-08-22 2008-01-30 株式会社ミツカングループ本社 筋肉損傷抑制組成物
KR101324076B1 (ko) 2005-09-22 2013-10-31 유키지루시 메그밀크 가부시키가이샤 스핑고미엘린 함유 의약, 음식품 또는 사료
EP1815745A1 (en) 2006-02-03 2007-08-08 Friesland Brands B.V. Cholesterol-lowering dairy products and methods for their preparation
NZ571807A (en) * 2006-04-07 2013-05-31 Megmilk Snow Brand Co Ltd Fat accumulation inhibitor
TWI589228B (zh) 2009-04-23 2017-07-01 S A Corman 降低膽固醇含量之奶產品
JP5689055B2 (ja) * 2009-05-13 2015-03-25 丸大食品株式会社 鳥皮由来スフィンゴミエリン含有物を有効成分とする抗高血糖及び／又は抗高脂血症剤
EP2811831B1 (en) 2012-02-07 2018-04-11 The Regents Of The University Of California Glycosphingolipids for use in modulating immune responses
WO2014059220A1 (en) 2012-10-12 2014-04-17 The Brigham And Women's Hospital, Inc. Glycosphingolipids and methods of use thereof
JP2016013083A (ja) * 2014-07-01 2016-01-28 花王株式会社 麺つゆ
JP6232008B2 (ja) * 2015-03-19 2017-11-15 国立大学法人北海道大学 酸化抑制剤及びこれを用いた油脂含有飲食品
US20170044516A1 (en) 2015-08-11 2017-02-16 Industrial Technology Research Institute Biochemistry reactive material and device for eliminating electronegative low-density lipoprotein (ldl) and method for treating blood or plasma ex vivo to eliminate electronegative low-density lipoprotein therein

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2492259A1 (fr) 1980-10-21 1982-04-23 Idinvex Sa Formulation d'heparine
JPS61152632A (ja) * 1984-12-26 1986-07-11 Dai Ichi Seiyaku Co Ltd 抗動脈硬化剤
JPS6344842A (ja) 1986-08-12 1988-02-25 Kao Corp 油中水中油型乳化油脂組成物
US4952567A (en) * 1988-05-09 1990-08-28 City Of Hope Inhibition of lipogenesis
IT1235162B (it) * 1988-12-02 1992-06-22 Fidia Farmaceutici Derivati di lisosfingolipidi
US5190876A (en) * 1988-12-27 1993-03-02 Emory University Method of modifying cellular differentiation and function and compositions therefor
US5231090A (en) * 1990-07-30 1993-07-27 University Of Miami Treatment for hypercholesterolemia
KR970004038B1 (ko) 1990-08-13 1997-03-24 듀크 유니버시티 세라미드를 활용하여 세포분화를 자극시키는 방법
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5232837A (en) * 1991-08-05 1993-08-03 Emory University Method of altering sphingolipid metabolism and detecting fumonisin ingestion and contamination
US5374616A (en) * 1991-10-18 1994-12-20 Georgetown University Compositions containing sphingosylphosphorylcholine and the use thereof as a cellular growth factor
US6190894B1 (en) * 1993-03-19 2001-02-20 The Regents Of The University Of California Method and compositions for disrupting the epithelial barrier function
US5478860A (en) * 1993-06-04 1995-12-26 Inex Pharmaceuticals Corp. Stable microemulsions for hydrophobic compound delivery
US5830853A (en) * 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
US6773719B2 (en) * 1994-03-04 2004-08-10 Esperion Luv Development, Inc. Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias
US20020182250A1 (en) * 1995-09-06 2002-12-05 Goro Hori Lipid metabolism improving agent
WO1997011706A1 (en) 1995-09-29 1997-04-03 Georgetown University Use of sphingosylphosphorylcholine as a wound-healing agent
DE19602108A1 (de) 1996-01-22 1997-07-24 Beiersdorf Ag Gegen Bakterien, Parasiten, Protozoen, Mycota und Viren wirksame Substanzen
AU2195297A (en) 1996-02-20 1997-09-02 Sloan-Kettering Institute For Cancer Research Combinations of pkc inhibitors and therapeutic agents for treating cancers
CN1222293C (zh) 1997-04-10 2005-10-12 麒麟麦酒株式会社 含有α－糖基神经酰胺的NKT细胞活化剂
US6800661B1 (en) * 1997-04-15 2004-10-05 Board Of Trustees Of The University Of Illinois Spisulosine compounds
US5989803A (en) * 1997-09-05 1999-11-23 The Trustees Of Columbia University In The City Of New York Method for treating a subject suffering from a condition associated with an extracellular zinc sphingomyelinase
WO1999041266A1 (en) 1998-02-12 1999-08-19 Emory University Sphingolipid derivatives and their methods of use
JP3581010B2 (ja) * 1998-03-18 2004-10-27 雪印乳業株式会社 脂質の消化吸収機能改善剤
AU4097999A (en) 1998-05-26 1999-12-13 Sarah Spiegel Sphingosine kinase, cloning, expression and methods of use
US6713057B1 (en) * 1999-02-24 2004-03-30 The Johns Hopkins University Compositions and methods for modulating serum cholesterol
EP1155121B1 (en) * 1999-02-24 2006-04-26 The Johns Hopkins University Compositions and methods for modulating serum cholesterol
JP3544493B2 (ja) * 1999-06-10 2004-07-21 雪印乳業株式会社 乳幼児用栄養組成物
KR100341793B1 (ko) 1999-07-02 2002-06-24 권 영 근 스핑고신 1-포스페이트를 유효성분으로 포함하는 혈관신생 촉진제
KR20020027463A (ko) * 1999-07-12 2002-04-13 우에노 도시오 스핀고신-1-인산 수용체 아고니스트 또는스핀고신-1-인산을 유효 성분으로서 함유하는 선유화 억제제
JP2001213858A (ja) 1999-11-24 2001-08-07 Sagami Chem Res Center スフィンゴシン誘導体
JP2001158735A (ja) 1999-11-30 2001-06-12 Snow Brand Milk Prod Co Ltd 歯周病の予防及び改善剤
JP2001158736A (ja) * 1999-11-30 2001-06-12 Snow Brand Milk Prod Co Ltd 骨関節疾患の予防及び改善剤
CA2400021A1 (en) 2000-02-18 2001-08-23 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
CA2402769A1 (en) 2000-03-28 2001-10-04 The Liposome Company, Inc. Ceramide derivatives and method of use
JP2002068998A (ja) 2000-08-29 2002-03-08 Meiji Milk Prod Co Ltd 経腸栄養および静脈栄養に伴う脂肪肝発生予防組成物
WO2002034062A1 (en) 2000-10-27 2002-05-02 Nv Marc Boone Method for obtaining products enriched in phospho- and sphingolipids
WO2002042698A1 (en) * 2000-11-22 2002-05-30 Kc & Aa, Inc. Portable cooler for beverage container
US6949247B2 (en) * 2000-12-28 2005-09-27 Unilever Home & Personal Care Usa Division Of Conopco, Inc. Stable skin care compositions containing a retinoid and a retinoid booster system
FR2820037B1 (fr) 2001-01-29 2005-12-09 Dermaconcept Jmc Composition dermatologique a usage veterinaire comprenant une base sphingoide
JP2002226394A (ja) * 2001-02-01 2002-08-14 Meiji Milk Prod Co Ltd 脂質代謝改善組成物
JP4958339B2 (ja) * 2001-03-21 2012-06-20 雪印メグミルク株式会社 脂質代謝改善剤
DK1406641T3 (da) * 2001-06-18 2009-05-04 Neptune Technologies & Bioress Krillekstrakter til forebyggelse og/eller behandling af cardiovaskulære sygdomme
ES2288193T3 (es) 2001-07-27 2008-01-01 NEPTUNE TECHNOLOGIES & BIORESSOURCES INC. Fosfolipidos naturales de origen marino que contienen flavonoides y fosfolipidos poliinsaturados y sus usos.
DE60117900D1 (de) 2001-09-05 2006-05-11 Charmzone Co Phytosphingosinderivate mit Antitumorwirkung
US20030109044A1 (en) * 2001-10-16 2003-06-12 Millennium Pharmaceuticals, Inc. Methods of using 279, a human G protein-coupled protein receptor
JP4035759B2 (ja) 2001-11-06 2008-01-23 独立行政法人産業技術総合研究所 アミノアルコールリン酸化合物、製造方法、及びその利用方法
DE10217555A1 (de) 2002-04-19 2004-02-19 Degussa Bioactives Deutschland Gmbh Physiologisch verträgliche, Phospholipid-haltige, stabile und harte Matrix
BR0310099A (pt) * 2002-05-17 2007-03-20 Esperion Therapeutics Inc método para tratar dislipidemia ou uma doença associada com a dislipidemia
EP1539125A4 (en) 2002-08-14 2005-09-14 Kim Tae Yoon COMPOSITION COMPRISING PHYTOSPHINGOSINE DERIVATIVES USEFUL IN THE INDUCTION OF APOPTOSIS
JP2006516280A (ja) 2003-01-20 2006-06-29 ネーデルランドセ オルガニサティエ フォール トエゲパストナトールヴェテンシャッペリク オンデルゾエク ティエヌオー 血漿コレステロール及びトリアシルグリセロールレベルを減少するためにスフィンゴ脂質を使用する方法
NL1022443C2 (nl) 2003-01-20 2004-07-22 Tno Sphingolipiden voor verbetering van de samenstelling van de darmflora.
GB0301395D0 (en) 2003-01-21 2003-02-19 Univ Aston Inflammatory disorder treatment
US9717754B2 (en) * 2003-02-27 2017-08-01 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
US20040171522A1 (en) 2003-02-27 2004-09-02 Yaron Ilan Regulation of immune responses by manipulation of intermediary metabolite levels
WO2004096140A2 (en) 2003-04-25 2004-11-11 The Penn State Research Foundation Method and system for systemic delivery of growth arresting, lipid-derived bioactive compounds

Also Published As

Publication number Publication date
US7968529B2 (en) 2011-06-28
JP2006516280A (ja) 2006-06-29
DE602004020316D1 (de) 2009-05-14
WO2004064820A3 (en) 2004-09-30
WO2004064820A2 (en) 2004-08-05
EP1585508A2 (en) 2005-10-19
ES2325260T3 (es) 2009-08-31
US20060189575A1 (en) 2006-08-24
EP1585508B1 (en) 2009-04-01

Similar Documents

Publication Publication Date Title
ATE427106T1 (de) Die verwendung von sphingolipiden zur senkung der cholesterin- und triglyzeridspiegel im plasma.
Bouwstra Stratum corneum lipids: their role for the skin barrier function in healthy subjects and atopic dermatitis patients
Moore et al. The chemistry, function and (patho) physiology of stratum corneum barrier ceramides
Rai et al. Novel lipidomic biomarkers in hyperlipidemia and cardiovascular diseases: an integrative biology analysis
Munoz‐Olaya et al. Synthesis and biological activity of a novel inhibitor of dihydroceramide desaturase
Moon et al. Altered levels of sphingosine and sphinganine in psoriatic epidermis
BR112013028440A2 (pt) composições e métodos que compreendem variantes de serina protease
BRPI0609393B8 (pt) usos de um composto 11-desóxi-prostaglandina
EP1749818A3 (en) Phenyl-piperazine derivatives as serotonin reuptake inhibitors
ATE539751T1 (de) Verwendung von brimonidine zur behandlung von stress assoziierten zuständen
MY161991A (en) Proteasome inhibitors
GB2459809A (en) Fatty acid formulations and methods of use thereof
Afanas’ ev Free radical mechanisms of aging processes under physiological conditions
ATE485262T1 (de) Verfahren zur herstellung von di- und polyaminen der diphenylmethanreihe
WO2005099716A3 (en) Method for analyzing the biological age of a subject
JP2006516280A5 (enExample)
TW200626160A (en) Memantine for the treatment of childhood behavioral disorders
Sugawara et al. Efflux of sphingoid bases by P-glycoprotein in human intestinal Caco-2 cells
GT200600115A (es) Metodo para identificar blancos terapeuticos para el tratamiento de atrofia vulvoginal
Kuo et al. Murine endothelial serine palmitoyltransferase 1 (SPTLC1) is required for vascular development and systemic sphingolipid homeostasis
DE602004016727D1 (de) Sphingolipiden zur verbesserung der darmflorazusammensetzung
Ordóñez et al. 3-Ketosphinganine provokes the accumulation of dihydroshingolipids and induces autophagy in cancer cells
WO2010028336A3 (en) Fatty acid c16:1n7-palmitoleate a lipokine and biomarker for metabolic status
ZA202309930B (en) Fragrance for improving relaxation state and method of assessing
GEP20156386B (en) New crystal form vii of agomelatine, preparation method and usage thereof, and pharmaceutical compositions containing thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties